title: Engineered CRISPR/Cas13d Virus-Like Particles for Potent, Safe Gene Therapy of Idiopathic Pulmonary Fibrosis
design: Mouse were given tracheal injections of BLM, and starting on day 7, therapeutic VLP was injected via the trachea every 2 days, with a total of 4 injections. Lung tissues were collected for sequencing, and the samples were divided into three parts  for sequencing.